19 NOVEMBER 2009, BOSTON - Zen Chu (Accelerated Medical Ventures and CIMIT's Innovation Grand Rounds) recently testified at the FDA's public hearings on Social Media and Internet (#FDASM). The FDA is grappling with a number of questions centered around regulation and accountability for Healthcare and the use of Social Media, with implications for direct-to-consumer advertising, patient safety, adverse event reporting, disease management, and new technology innovation.
The FDA thought it wise to bring together qualified experts from a wide range of areas to give testimony. Streaming video available for the next 20 days: http://www.fdasm.com/
I thought Zen had an interesting testimony, perspective and has shared it with us.
Zen Chu: My purpose was to lend an innovation and new ventures perspective to the FDA panel:
- FDA should lend clarity to regulations and exercise restraint to enable new technologies and services to engage patients
- FDA needs to distinguish between ads and messages delivered to benefit wellness, compliance, adherence
- FDA must hire more expertise in new media and technology to understand and provide more timely guidelines
- A New Media & Technology Advisory Board, comprise of both industry, academia and patient advocates should be created to advise FDA
Recent Comments